drugset / Trial / NCT01254721

A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study

NCT01254721

Phase 4 Terminated 131 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to compare the efficacy of Seroquel XR monotherapy compared with Seroquel XR plus lithium in the treatment of acute bipolar mania by evaluation of the changes from baseline in Young Mania Ratings Scale (YMRS) total score to Day 29 using the last observation carried forward method.

Timeline

Start
2010-12
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lithium Unknown 300 mg Oral
Subject Quetiapine Small molecule 50 mg Oral
Subject Quetiapine Small molecule 200 mg Oral
Subject Quetiapine Small molecule 300 mg Oral
Subject Quetiapine Small molecule 400 mg Oral